222 related articles for article (PubMed ID: 8613910)
1. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland.
Inoue T; Domae M; Yamada K; Furukawa T
J Pharmacol Exp Ther; 1996 Apr; 277(1):137-43. PubMed ID: 8613910
[TBL] [Abstract][Full Text] [Related]
2. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
[TBL] [Abstract][Full Text] [Related]
3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
5. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area.
Momiyama T; Amano T; Todo N; Sasa M
Eur J Pharmacol; 1996 Aug; 310(1):1-8. PubMed ID: 8880060
[TBL] [Abstract][Full Text] [Related]
6. Decrease of prolactin secretion via stimulation of pituitary dopamine D-2 receptors after application of talipexole and SND 919.
Domae M; Yamada K; Hanabusa Y; Matsumoto S; Furukawa T
Eur J Pharmacol; 1990 Apr; 179(1-2):75-82. PubMed ID: 2142088
[TBL] [Abstract][Full Text] [Related]
7. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.
Lawler CP; Prioleau C; Lewis MM; Mak C; Jiang D; Schetz JA; Gonzalez AM; Sibley DR; Mailman RB
Neuropsychopharmacology; 1999 Jun; 20(6):612-27. PubMed ID: 10327430
[TBL] [Abstract][Full Text] [Related]
8. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats.
Fujikawa M; Nagashima M; Inoue T; Yamada K; Furukawa T
Pharmacol Biochem Behav; 1996 Apr; 53(4):903-9. PubMed ID: 8801596
[TBL] [Abstract][Full Text] [Related]
9. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
10. Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release in rat striatal slices.
Yamada S; Harano M; Yokoo H; Tanaka M
J Pharm Pharmacol; 1997 Feb; 49(2):206-8. PubMed ID: 9055196
[TBL] [Abstract][Full Text] [Related]
11. Effect of yohimbine on rat prolactin secretion.
Meltzer HY; Simonovic M; Gudelsky GA
J Pharmacol Exp Ther; 1983 Jan; 224(1):21-7. PubMed ID: 6294278
[TBL] [Abstract][Full Text] [Related]
12. Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro.
Meller E; Puza T; Miller JC; Friedhoff AJ; Schweitzer JW
J Pharmacol Exp Ther; 1991 May; 257(2):668-75. PubMed ID: 1674531
[TBL] [Abstract][Full Text] [Related]
13. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion.
Veselinović T; Schorn H; Vernaleken IB; Schiffl K; Klomp M; Gründer G
J Clin Psychopharmacol; 2011 Apr; 31(2):214-20. PubMed ID: 21346608
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats.
Oshibuchi H; Inada K; Sugawara H; Ishigooka J
Eur J Pharmacol; 2009 Aug; 615(1-3):83-90. PubMed ID: 19477171
[TBL] [Abstract][Full Text] [Related]
15. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Oshiro Y; Sato S; Kurahashi N; Tanaka T; Kikuchi T; Tottori K; Uwahodo Y; Nishi T
J Med Chem; 1998 Feb; 41(5):658-67. PubMed ID: 9513593
[TBL] [Abstract][Full Text] [Related]
16. Sodium ions: their role and mechanism of action in the control of prolactin release.
Collu R; Lafond J; Marchisio AM; Eljarmak D; Ducharme JR
Endocrinology; 1984 Apr; 114(4):1302-7. PubMed ID: 6423371
[TBL] [Abstract][Full Text] [Related]
17. Adenohypophysial dopamine content and prolactin secretion in the aged male and female rat.
Demarest KT; Moore KE; Riegle GD
Endocrinology; 1985 Apr; 116(4):1316-23. PubMed ID: 3971917
[TBL] [Abstract][Full Text] [Related]
18. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary.
Inoue A; Seto M; Sugita S; Hide I; Hirose T; Koga N; Kikuchi T; Nakata Y
Brain Res Mol Brain Res; 1998 Apr; 55(2):285-92. PubMed ID: 9582438
[TBL] [Abstract][Full Text] [Related]
19. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.
Bowden CR; Voina SJ; Woestenborghs R; De Coster R; Heykants J
J Pharmacol Exp Ther; 1992 Aug; 262(2):699-706. PubMed ID: 1380082
[TBL] [Abstract][Full Text] [Related]
20. Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens.
Amano T; Matsubayashi H; Momiyama T; Ishihara K; Todo N; Sasa M
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jan; 19(1):105-16. PubMed ID: 7708924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
